» Articles » PMID: 11172040

Integrin Activation Controls Metastasis in Human Breast Cancer

Overview
Specialty Science
Date 2001 Feb 15
PMID 11172040
Citations 237
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis is the primary cause of death in human breast cancer. Metastasis to bone, lungs, liver, and brain involves dissemination of breast cancer cells via the bloodstream and requires adhesion within the vasculature. Blood cell adhesion within the vasculature depends on integrins, a family of transmembrane adhesion receptors, and is regulated by integrin activation. Here we show that integrin alpha v beta 3 supports breast cancer cell attachment under blood flow conditions in an activation-dependent manner. Integrin alpha v beta 3 was found in two distinct functional states in human breast cancer cells. The activated, but not the nonactivated, state supported tumor cell arrest during blood flow through interaction with platelets. Importantly, activated alpha v beta 3 was expressed by freshly isolated metastatic human breast cancer cells and variants of the MDA-MB 435 human breast cancer cell line, derived from mammary fat pad tumors or distant metastases in severe combined immunodeficient mice. Expression of constitutively activated mutant alpha v beta 3(D723R), but not alpha v beta 3(WT), in MDA-MB 435 cells strongly promoted metastasis in the mouse model. Thus breast cancer cells can exhibit a platelet-interactive and metastatic phenotype that is controlled by the activation of integrin alpha v beta 3. Consequently, alterations within tumors that lead to the aberrant control of integrin activation are expected to adversely affect the course of human breast cancer.

Citing Articles

A machine learning-based investigation of integrin expression patterns in cancer and metastasis.

Shadman H, Gomrok S, Litle C, Cheng Q, Jiang Y, Huang X Sci Rep. 2025; 15(1):5270.

PMID: 39939698 PMC: 11821851. DOI: 10.1038/s41598-025-89497-w.


Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.

Kandav G, Chandel A Med Oncol. 2024; 41(11):275.

PMID: 39400611 DOI: 10.1007/s12032-024-02491-6.


Von Willebrand factor and hematogenous cancer metastasis under flow.

Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.

PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.


Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists.

Throup A, Zraikat M, Gordon A, Jafarinejad Soumehsaraei S, Haase K, Patterson L RSC Med Chem. 2024; .

PMID: 39281803 PMC: 11393731. DOI: 10.1039/d4md00306c.


Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.

Tang M, Zhang Z, Wang P, Zhao F, Miao L, Wang Y Acta Pharm Sin B. 2024; 14(8):3457-3475.

PMID: 39220884 PMC: 11365446. DOI: 10.1016/j.apsb.2024.04.034.


References
1.
Pischel K, Bluestein H, Woods Jr V . Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. J Clin Invest. 1988; 81(2):505-13. PMC: 329598. DOI: 10.1172/JCI113348. View

2.
Cheresh D, Spiro R . Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987; 262(36):17703-11. View

3.
Lam S, Plow E, DSouza S, Cheresh D, Frelinger 3rd A, Ginsberg M . Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. J Biol Chem. 1989; 264(7):3742-9. View

4.
Price J, Polyzos A, Zhang R, Daniels L . Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990; 50(3):717-21. View

5.
Dinota A, Tazzari P, Michieli M, Visani G, Gobbi M, Bontadini A . In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody. Cancer Res. 1990; 50(14):4291-4. View